The US Congressional Budget Office projects that revisions to the Medicare price negotiation provisions in the drug pricing reform legislation released recently by the Senate Finance Committee will produce nearly $23bn more savings to the federal government than the version approved by the House last fall. Savings from negotiation are now expected to reach $101.8bn, according to the score released by CBO 8 June.
The higher projections could be due to a more explicit requirement in the Senate bill that a certain number of...






